{"id":9013,"date":"2021-05-25T10:20:00","date_gmt":"2021-05-25T08:20:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/"},"modified":"2026-05-05T22:11:59","modified_gmt":"2026-05-05T20:11:59","slug":"irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","title":{"rendered":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P"},"content":{"rendered":"
IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research & Perspectives (PR&P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.<\/strong><\/div>\n

Den vetenskapliga artikeln beskriver den prospektiva, singel-center, randomiserade, dubbelblinda, placebokontrollerade Fas I- first-in-human (FIH)-studien med mesdopetam. Studien utv\u00e4rderade s\u00e4kerhet, tolerabilitet och farmakokinetik f\u00f6r eskalerande singeldoser och multipla doser av mesdopetam. Slutsatsen var att mesdopetam var s\u00e4kert och tolererades v\u00e4l hos friska manliga frivilliga f\u00f6rs\u00f6kspersoner. Farmakokinetisk analys visade p\u00e5 snabb absorption och doslinj\u00e4r farmakokinetik f\u00f6r mesdopetam vid enstaka och vid upprepade doser. Farmakokinetiken f\u00f6r mesdopetam st\u00f6der anv\u00e4ndning tv\u00e5 g\u00e5nger dagligen f\u00f6r patienter.<\/span><\/span><\/span><\/p>\n

\u201dDen publicerade artikeln f\u00f6r mesdopetams Fas I-studie st\u00e4rker det v\u00e4xande vetenskapliga st\u00f6det f\u00f6r l\u00e4kemedelskandidatens betydande potential vid Parkinsons sjukdom. Publicering av PR&P g\u00f6r det m\u00f6jligt f\u00f6r v\u00e5ra studieresultat att n\u00e5 en bred publik\u201d, s\u00e4ger Susanna Waters, MD och Ph.D., Director of Biology & Biostatistics p\u00e5 IRLAB.<\/span><\/span><\/span><\/p>\n

Tidskriften Pharmacology Research & Perspectives<\/em> (PR&P) publiceras gemensamt av American Society for Pharmacology and Experimental Therapeutics<\/em> (ASPET), British Pharmacological Society<\/em> (BPS) och Wiley. Tidskriften inkluderar fr\u00e4mst omr\u00e5dena nya farmakologiska hypoteser, verkningsmekanism, identifiering av m\u00e5lmolekyler och preklinisk och klinisk validering, l\u00e4kemedelsuppt\u00e4ckt, banbrytande uppt\u00e4ckter inom translationell medicin samt replikationsstudier.<\/span><\/span><\/span><\/p>\n

Artikel: Sj\u00f6berg F, Waters S, L\u00f6fberg B, Sonesson C, Waters N, Tedroff J. A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. Pharmacol Res Perspect.<\/em> 2021;9:e00792. https:\/\/doi.org\/10.1002\/prp2.792<\/a>.<\/span><\/span><\/span><\/p>\n

\n

F\u00f6r mer information<\/span><\/span><\/span><\/span><\/span><\/p>\n

Susanna Waters, Director of Biology & Biostatistics
\nTel: +46 730 75 77 02
\nE-post: susanna.waters@irlab.se<\/a> <\/span><\/span><\/span><\/span><\/p>\n

Joakim Tedroff, CMO
\nTel: +46 70 760 16 91
\nE-post: joakim.tedroff@irlab.se<\/u><\/span> <\/span><\/span><\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som
\nbeskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten
\nmesdopetam har publicerats i tidskriften Pharmacology Research & Perspectives
\n(PR&P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en
\ninternationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade
\ndyskinesier (LIDs) vid Parkinsons sjukdom.<\/p>\n","protected":false},"template":"","class_list":["post-9013","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research & Perspectives (PR&P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T20:11:59+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\",\"name\":\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2021-05-25T08:20:00+00:00\",\"dateModified\":\"2026-05-05T20:11:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P - IRLAB","og_description":"IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research & Perspectives (PR&P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","og_site_name":"IRLAB","article_modified_time":"2026-05-05T20:11:59+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","name":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2021-05-25T08:20:00+00:00","dateModified":"2026-05-05T20:11:59+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}